HI
IMVT icon

Harbour Investments’s Immunovant IMVT Stock Holding History

Harbour Investments’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$248 Buy
+10
New +$259 ﹤0.01% 4407
2023
Q4 		– Sell
-43
Closed -$1.65K – 3156
2023
Q3 		$1.65K Buy
+43
New +$972 ﹤0.01% 2597

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Harbour Investments's IMVT Position: Q1 2026 in Review

Harbour Investments opened a new position in Immunovant (IMVT) in Q1 2026: 10 shares worth $248. The stake represents ﹤0.01% of the portfolio and ranks #4407 among its holdings. This is a return to the name: Harbour Investments previously reported a position in IMVT as recently as Q3 2023.

Harbour Investments first reported a position in IMVT in Q3 2023 and has held it in 2 quarters since. The position peaked at $1.65K in Q3 2023. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • Harbour Investments held 10 shares of Immunovant worth $248 as of Q1 2026.
  • Immunovant was a new Harbour Investments position in Q1 2026.
  • Immunovant made up ﹤0.01% of Harbour Investments's portfolio in Q1 2026, its #4407 holding.
  • Harbour Investments first reported a position in Immunovant in Q3 2023 and has held it in 2 quarters since.
  • Harbour Investments's Immunovant position peaked at $1.65K in Q3 2023.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Harbour Investments's 13F filing for Q1 2026, filed 15 May 2026.